BioWorld - Monday, February 17, 2025
See today's BioWorld
To read the full story, subscribe or sign in.
European Society for Medical Oncology 2022

Genexine’s therapeutic DNA vaccine could extend survival in late-stage cervical cancer

Sep. 9, 2022
By Tamra Sami
No Comments
Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab).
BioWorld Conferences European Society for Medical Oncology Cancer